Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) announced the initiation of polymer process development and analytical characterization activities by Nanosoft Polymers in support of ONC010, the company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. This step is critical for advancing the drug candidate toward clinical trials and eventual commercialization.
The polymer development work includes optimization of synthesis, characterization methodology, molecular weight assessment, purification strategy refinement, and manufacturing scalability assessments. These activities are part of Onco-Innovations’ chemistry, manufacturing and controls (CMC) strategy aimed at establishing a scalable, reproducible, and analytically characterized polymer platform. Such a platform is essential to support future formulation, manufacturing, regulatory filings, and clinical development.
Onco-Innovations said that Nanosoft’s expertise in polymer science and nanoparticle drug delivery is expected to strengthen the technical foundation of the ONC010 platform while supporting future GMP manufacturing readiness. The collaboration underscores the company’s commitment to developing innovative cancer treatments that target solid tumors.
ONC010 is a nanoparticle-formulated inhibitor of PNKP, an enzyme involved in DNA repair that is often overexpressed in cancer cells. By inhibiting PNKP, ONC010 may enhance the effectiveness of DNA-damaging therapies and provide a new approach to treating solid tumors. The nanoparticle formulation is designed to improve drug delivery and efficacy while reducing side effects.
The importance of this development lies in the potential to bring a novel cancer therapy closer to patients. Effective CMC development is a prerequisite for regulatory approval and commercial-scale production. By partnering with Nanosoft, Onco-Innovations aims to de-risk the manufacturing process and ensure that ONC010 can be produced consistently and at scale.
For investors and the oncology industry, this announcement signals progress in the pipeline and a strategic move to address manufacturing challenges early in development. The success of these activities could accelerate the timeline for ONC010 to enter clinical trials and ultimately reach the market.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. For more information, visit the company’s newsroom at https://nnw.fm/ONNVF. The full press release is available at https://nnw.fm/BeSoS.
